Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

Balasubramanian, P.; Wanner, C.; Pedro P. Ferreira, Joao; P. Ofstad, A.; Elsaesser, A.; Zinman, B.; E. Inzucchi, S.

doi:10.37987/1997-9894.2022.5-6(261-2).271666

Public

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

Published in Medicine of Ukraine • Sep 14, 2022

Authors:

P. Balasubramanian

C. Wanner

Joao Pedro P. Ferreira

Abstract

Diabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists. Aim: we examined the association between nephroli...

Subject

Empagliflozin

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!